Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.68
-2.2%
$0.85
$0.65
$3.02
$30.90M2.851.05 million shs898,752 shs
MAAQ
Mana Capital Acquisition
$3.79
+1.2%
$3.90
$5.35
$10.25
$30.79MN/A33,075 shs15,581 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$4.45
-2.4%
$3.63
$1.75
$6.92
$7.49M1.253.90 million shs40,453 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$5.95
-1.7%
$2.17
$0.95
$9.08
$34.43M1.1730.49 million shs5.47 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-2.20%-9.03%-9.64%-32.99%-38.47%
MAAQ
Mana Capital Acquisition
+1.20%+4.12%-13.61%-5.01%+860.22%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-2.41%-12.57%+44.01%+29.36%+2,635.10%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-1.65%+26.06%+350.76%+299.33%+104.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.5286 of 5 stars
3.53.00.00.03.31.70.0
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
3.4004 of 5 stars
3.85.00.00.02.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.001,229.79% Upside
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
3.50
Strong Buy$17.00185.71% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.09) per shareN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.51N/AN/A$2.47 per share1.80
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.06 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.85N/AN/AN/AN/A-65.01%11/13/2025 (Estimated)
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.46N/AN/AN/A-23.87%-50.00%-16.79%11/6/2025 (Estimated)
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$6.10N/AN/AN/A-1,239.20%-365.06%N/A

Latest SNOA, ITRM, MAAQ, and THAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$0.58-$0.64-$0.06-$0.64N/AN/A
8/7/2025Q1 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.51-$0.37+$0.14-$0.76$4.26 million$4.01 million
8/5/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13-$0.16-$0.03-$0.16N/AN/A
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.69
2.52
MAAQ
Mana Capital Acquisition
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.70
1.92
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
1.17
1.17

Institutional Ownership

CompanyInstitutional Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
MAAQ
Mana Capital Acquisition
68.44%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%

Insider Ownership

CompanyInsider Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.40%
MAAQ
Mana Capital Acquisition
N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
24.59%
Tharimmune, Inc. stock logo
THAR
Tharimmune
10.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1044.66 million43.59 millionNot Optionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.24 millionNot Optionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
25.69 million4.80 millionNot Optionable

Recent News About These Companies

Biotech Stocks To Watch Today - August 25th
Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale
Why Is Tharimmune Stock (THAR) Blowing Up?
Why Is Tharimmune Stock (THAR) Exploding Higher?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.68 -0.02 (-2.20%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$0.70 +0.02 (+2.69%)
As of 08/29/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mana Capital Acquisition NASDAQ:MAAQ

$3.79 +0.05 (+1.20%)
As of 08/28/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$4.45 -0.11 (-2.41%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$4.42 -0.03 (-0.56%)
As of 08/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$5.95 -0.10 (-1.65%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.85 -0.10 (-1.66%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.